262 related articles for article (PubMed ID: 29402932)
1. BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1.
Zhu S; Zhao D; Yan L; Jiang W; Kim JS; Gu B; Liu Q; Wang R; Xia B; Zhao JC; Song G; Mi W; Wang RF; Shi X; Lam HM; Dong X; Yu J; Chen K; Cao Q
Nat Commun; 2018 Feb; 9(1):500. PubMed ID: 29402932
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
4. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of
Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
[TBL] [Abstract][Full Text] [Related]
6. Targeted Degradation of PRC1 Components, BMI1 and RING1B, via a Novel Protein Complex Degrader Strategy.
Park KS; Qin L; Kabir M; Luo K; Dale B; Zhong Y; Kim A; Wang GG; Kaniskan HÜ; Jin J
Adv Sci (Weinh); 2023 Apr; 10(10):e2205573. PubMed ID: 36737841
[TBL] [Abstract][Full Text] [Related]
7. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells.
Kregel S; Szmulewitz RZ; Vander Griend DJ
Prostate; 2014 Nov; 74(15):1530-43. PubMed ID: 25175748
[TBL] [Abstract][Full Text] [Related]
8. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
[TBL] [Abstract][Full Text] [Related]
9. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
[TBL] [Abstract][Full Text] [Related]
10. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
[TBL] [Abstract][Full Text] [Related]
12. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.
Kwegyir-Afful AK; Ramalingam S; Purushottamachar P; Ramamurthy VP; Njar VC
Oncotarget; 2015 Sep; 6(29):27440-60. PubMed ID: 26196320
[TBL] [Abstract][Full Text] [Related]
13. Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance.
Wu H; You L; Li Y; Zhao Z; Shi G; Chen Z; Wang Z; Li X; Du S; Ye W; Gao X; Duan J; Cheng Y; Tao W; Bian J; Zhou JR; Zhu Q; Yang Y
Cancer Res; 2020 Jul; 80(13):2927-2939. PubMed ID: 32341037
[TBL] [Abstract][Full Text] [Related]
14. Selective degradation of AR-V7 to overcome castration resistance of prostate cancer.
Liu Y; Yu C; Shao Z; Xia X; Hu T; Kong W; He X; Sun W; Deng Y; Liao Y; Huang H
Cell Death Dis; 2021 Sep; 12(10):857. PubMed ID: 34548474
[TBL] [Abstract][Full Text] [Related]
15. TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression.
Feng T; Zhao R; Sun F; Lu Q; Wang X; Hu J; Wang S; Gao L; Zhou Q; Xiong X; Dong X; Wang L; Han B
Oncogene; 2020 Jan; 39(2):356-367. PubMed ID: 31477836
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells.
de Las Pozas A; Reiner T; De Cesare V; Trost M; Perez-Stable C
Sci Rep; 2018 Sep; 8(1):13146. PubMed ID: 30177856
[TBL] [Abstract][Full Text] [Related]
17. AR-v7 protein expression is regulated by protein kinase and phosphatase.
Li Y; Xie N; Gleave ME; Rennie PS; Dong X
Oncotarget; 2015 Oct; 6(32):33743-54. PubMed ID: 26378044
[TBL] [Abstract][Full Text] [Related]
18. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
19. AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
Hettel D; Zhang A; Alyamani M; Berk M; Sharifi N
Endocrinology; 2018 Aug; 159(8):2884-2890. PubMed ID: 29850791
[TBL] [Abstract][Full Text] [Related]
20. Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer.
Kato M; Banuelos CA; Imamura Y; Leung JK; Caley DP; Wang J; Mawji NR; Sadar MD
Clin Cancer Res; 2016 Jun; 22(11):2744-54. PubMed ID: 26712685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]